EGM Statement

RNS Number:2212P
Xenova Group PLC
01 September 2003


Xenova Group Plc EGM Statement

Xenova Group Plc 1 September 2003


Not for release, publication or distribution in or into the United States,
Canada, Australia or Japan

Xenova Group plc ("Xenova") Recommended Offer for KS Biomedix Holdings Plc ("KS
Biomedix")

Result of Extraordinary General Meeting

Xenova announces that, at an Extraordinary General Meeting held earlier today,
the resolutions relating to the recommended Offer by Nomura International plc
("Nomura") on behalf of Xenova for KS Biomedix (the "Offer") were duly passed.

The first closing date of the Offer is 4 September 2003. KS Biomedix
shareholders are reminded that acceptances of the Offer should be returned as
soon as possible and in any event so as to be received by no later than 3.00
p.m. on that day.

Enquiries:
David Oxlade, Xenova                                   01753 706600
David Rasouly, Nomura                                  020 7521 2000
David Yates, Financial Dynamics                        020 7831 3113



Nomura, is acting exclusively for Xenova in connection with the Offer and is not
advising any other person or treating any other person as its client in relation
thereto and will not be responsible to anyone other than Xenova for providing
the protections afforded to clients of Nomura or for providing advice in
relation to the Offer or the New Xenova Shares.

This announcement does not constitute an offer or an invitation to purchase any
securities.

This announcement does not constitute an offer of securities for sale in the
United States and the New Xenova Shares have not been, and will not be,
registered under the United States Securities Act of 1933, as amended, nor under
any laws of any state of the United States, and the relevant clearances have not
been and will not be obtained from the relevant authorities in Canada, Australia
or Japan.  Accordingly, unless an exemption under any applicable laws is
available, the New Xenova Shares may not be offered, sold, resold, delivered or
transferred directly or indirectly, in or into the United States, Canada,
Australia or Japan or any other country outside the United Kingdom where such
distribution may otherwise lead to a breach of law or other regulatory
requirement, or to or for the benefit of US Persons.

The Offer referred to in this announcement is not being made, directly or
indirectly, in or into, or by use of the mails of or by any means of
instrumentality (including, without limitation, facsimile transmissions, telex,
telephone or internet) or interstate or foreign commerce of, or any facilities
of a securities exchange of, the United States, nor is it being made, directly
or indirectly, to or for the benefit of US Persons, nor is it being made,
directly or indirectly, in or into Canada, Australia, or Japan unless an
exemption under any applicable laws is available.  This announcement is not
being, and it must not be, mailed or otherwise forwarded, distributed or sent
in, or into the United States, Canada, Australia or Japan and doing so may
render invalid any purported acceptance of the Offer.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EGMEAENFESEDEFE